Neoral induction in pediatric renal transplantation by Kershaw, David B. et al.
Transplantation
Original article
Neoral induction in pediatric renal transplantation
Timothy E. Bunchman, Rulan S. Parekh, Joseph T. Flynn, William E. Smoyer, David B. Kershaw,
Rudolph P. Valentini, Brenda J. Pontillo, Jill Sandvordenker, Catherine Brown, and Aileen B. Sedman
Division of Pediatric Nephrology, University of Michigan, Michigan, USA
Received August 21, 1996; received in revised form June 27, 1997; accepted June 30, 1997
Abstract. Neoral was instituted in pediatric renal transplant
patients with the hypothesis it would have more predictable
kinetics than Sandimmun. However, significant questions
have arisen concerning potential toxicity and dosing inter-
val related to its rapid absorption with subsequent high
initial peak. This is compounded by the fact that children
appear to metabolize cyclosporine at a greater rate than
adults. This combination of a rapid peak and rapid ab-
sorption may then result in lower trough levels at 12 h. We
compared the trough cyclosporine levels of nine children
who received Neoral with nine who received Sandimmun at
the time of initial transplantation. More frequent dosing
(every 8 h) was required in the Neoral population compared
with the Sandimmun population for the 1st month in order
to obtain comparable trough levels. Beyond the initial 4±6
weeks, trough levels were similar for Neoral and Sandim-
mun. Whereas 1-month creatinine levels and blood pres-
sures were similar, the number of blood pressure medica-
tions was significantly higher in the Neoral group. At 5.5
+ 1.1 months' followup, a single patient in the current
Neoral group and in the retrospective Sandimmun group
each experienced a single OKT3 allograft-treated rejection.
We suggest that the area under the curve is different in
Neoral than Sandimmun, and the initial dosing frequency
may need to be adjusted accordingly.
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Introduction
Transplantation has become common practice in the pedi-
atric patient with end-stage renal disease (ESRD). Evalu-
ation of immunosuppression protocol demonstrates that
cyclosporine (CSA) has been an important medication for
both induction and stability of treatment for renal trans-
plantation. Prior to 1996, the available form of CSA was
Sandimmun. Since the introduction of Sandimmun, allo-
graft survival has improved compared with historical con-
trols pre CSA [1, 2].
It has been evident over the last decade that, depending
upon the age of the patients, the kinetics of the metabolism
of Sandimmun varies [3, 4]: the younger the patient the
more rapidly Sandimmun is metabolized [2±4]. In order to
obtain target trough levels of CSA, one may increase the
dose or change the dosing frequency. Increasing the dose of
Sandimmun results in a higher peak concentration level. By
shortening the dosing interval one may obtain lower peak
levels, although a higher total daily dose of CSA may be
prescribed.
Data from the North American Pediatric Renal Trans-
plant Cooperative Study (NAPRTCS) have demonstrated
that higher Sandimmun dosing has a positive impact on
post-transplantation allograft survival [5]. Because the
NAPRTCS database does not look at levels but looks at
prescribed milligrams per kilogram of Sandimmun per day
one cannot say absolutely that higher levels affect outcome.
It is evident though that the higher dose most likely results
in higher CSA levels improving allograft survival.
Over the last year, a new form of CSA (Neoral), which
was developed to provide more reliable absorption, has
become available. The concern in the pediatric community
is that by more rapid absorption Neoral may give a higher
peak but shift the curve to the left (i.e., closer to the time of
per os intake) [6]. Due to the fact that children have his-
torically metabolized CSA at a more rapid rate than adults,
Neoral may require more frequent dosing in order to obtain
the desired target trough levels. With that in mind, we
evaluated the use of Neoral in our renal transplant patients.
Materials and methods
Patients who underwent renal transplantation from September 1995 to
May 1996 are included (n = 9). These children (aged 11.5 + 1.5 years;
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weight 35.1 + 3.1 kg, mean + SEM) included five females and four
males. Causes of ESRD included: hemolytic uremic syndrome (1),
renal dysplasia (4), obstructive uropathy (2), and focal sclerosis (2).
Seven of nine children received a living-related donor kidney and none
underwent native kidney nephrectomy for hypertension control. The
average number of antihypertensive agents each patient was on prior to
transplantation was 2.1 per child.
We matched these nine children by age, sex, etiology of ESRD,
pre-transplant hypertension, and donor source with nine children
transplanted with an identical protocol except for Sandimmun. Seven
of nine children received a living-related donor kidney and none
underwent native kidney nephrectomy for hypertension control. The
average number of antihypertensive agents that each patient was on
prior to transplantation was 1.9 per child.
All children (regardless of whether they received Neoral or
Sandimmun) underwent our usual induction protocol, including 10
days of ATGAM (15 mg/kg per day, UpJohn, Kalamazoo, Mich.,
USA), prednisone (2 mg/kg per day with taper), azathioprine (2 mg/kg
per day maintaining absolute with blood cell count 44,000), and
Sandimmun [14 mg/kg per day divided every 12 h or 500 mg/m2 per
day (in children 56 years) divided every 8 h]. Independent of dosing
frequency, the CSA trough target level is 150±200 ng/ml as measured
by whole blood trough high-performance liquid chromatography
(HPLC). CSA is begun when the post-transplant creatinine is 50% or
less of the pre-transplant creatinine, which occurred in 89% of children
in both groups within 24 h of transplantation. Experience with this
dosing of Sandimmun demonstrated therapeutic levels (i.e., 4150 ng/
ml) of CSA within 24 h of beginning Sandimmun [4].
Previous experience has demonstrated a 14% incidence of break-
through rejection during polyclonal T-cell induction when the San-
dimmun was begun on days 5 or 6 post transplantation [7]. Since
beginning CSA earlier and obtaining therapeutic levels sooner, we
have had no further rejection during induction [4].
When applicable, statistical analysis was performed using Stu-
dent's t-test and considered significant at P 50.05.
Results
The first of these children (a 10-year-old female) under-
went the usual induction of 14 mg/kg per day Neoral di-
vided every 12 h. Trough levels of Neoral after 3 days of
oral administration demonstrated our inability to obtain
adequate target trough levels (150±200 ng/ml, HPLC).
Upon increasing the dose by 10% and adjusting the fre-
quency from every 12 h to 8 h, therapeutic levels of Neoral
were obtained (Fig. 1). Because of the course of this child,
the subsequent eight children were induced with Neoral
500 mg/m2 per day (approximately 21 mg/kg per day) di-
vided every 8 h. Therapeutic levels of Neoral were obtained
within 24 h of transplant (Fig. 2). At 1 month, with iden-
tical target CSA levels obtained, similar dosing of Neoral as
Sandimmun is demonstrated (Fig. 3).
In the first 6 months post transplantation, four children
underwent a transplant biopsy for suspected rejection
(based upon elevated creatinine compared with discharge
baseline) and the histology revealed no pathological diag-
nosis in three. Upon reducing the Neoral dose, creatinine
levels stabilized. A single child in each group had OKT3-
reversed rejection at 6 weeks post transplantation (Table 1).
We next compared the serum creatinine levels, blood
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Fig. 1. Cyclosporine levels and Neoral dose in one patient. Therapeutic
cyclosporine levels were immediately obtained upon changing from
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Fig. 3. Cyclosporine dosage and dosing frequency in children matched
for age, sex, and cause of end-stage renal disease re-entering either
Sandimmun or Neoral according to time post transplantation
Sandimmun
Neoral
between the Neoral and the Sandimmun group at 1 month
post transplantation. The serum creatinine levels were
1.1 + 0.2 versus 1.1 + 0.2 mg/dl (NS), the number of
blood pressure medications was 2.7+ 0.2 versus 0.75+ 0.5
(P 50.05), and the mean blood pressure was 122/70 versus
131/78 mmHg (NS) in the Neoral and the Sandimmun
group, respectively (Table 1).
At 5.5 + 1.1 months followup, one child in the Neoral
group has had a rejection episode. The mean creatinine
level of the Neoral group is 1.1 + 0.2 mg/dl as compared
with 1.0 + 0.2 mg/dl for the Sandimmun group (NS). The
number of blood pressure medications is 2 + 0.9 versus
0.5 + 0.3 (P 5 0.05), while the mean blood pressures are
similar (115/69 vs. 133/78 mmHg) in the Neoral and San-
dimmun group, respectively.
Discussion
Experience suggests that a trough level in a known thera-
peutic range (in our case 150±200 ng/ml by HPLC) pro-
vides adequate immunosuppression in most patients re-
ceiving Sandimmun. An alternative method for monitoring
CSA exposure would be to measure the area under the
curve (AUC). The correlation between trough CSA levels
and AUC is not well established, but appears to vary sig-
nificantly from patient to patient [8]. The factors that affect
the AUC would obviously be the peak level as well as the
metabolism and clearance rates. Those patients with a high
peak level with a slow metabolism will have a higher AUC
than patients with low peak levels and a rapid metabolism.
Since calculation of AUC requires multiple samples, trough
levels have been used in most transplant centers.
The use of Neoral in patients has been suggested to give
improved immunosuppression because of more-reliable
absorption. Certainly data on patients being transitioned
from Sandimmun to Neoral suggest that the AUC may be
increased by almost 40% in the Neoral arm as opposed to
the Sandimmun arm [9, 10]. Bokenkamp et al. [9] con-
verted ten children on a one-to-one basis from Sandimmun
to Neoral; 60% of those children exhibited a diminished
creatinine clearance which normalized after the Neoral
dose was decreased. They found that they could prescribe
3%±5% less CSA by decreasing the Neoral dose using the
child's previous serum creatinine as the judge of adequacy
(and toxicity) of CSA therapy. This suggests that by low-
ering the target CSA trough levels, adequate im-
munosuppression from Neoral can be obtained while
minimizing CSA toxicity. This might be explained by a
higher AUC for Neoral than Sandimmun when similar
trough levels are achieved. Neoral may provide higher
exposure to CSA, which may be beneficial for im-
munosuppression but potentially toxic.
In our experience when we administer Neoral every 12 h
we are unable to achieve therapeutic CSA levels within 3±4
days of transplant. Only by increasing the frequency of
dosing from every 12 to 8 h are we able to obtain a ther-
apeutic trough level.
More frequent dosing of Neoral may affect compliance
as well as require more planning by families and health-
care givers. Within 1 month post transplantation all patients
were able to change from 8-h to 12-h dosing. We presume
this may be related to saturation of lipid stores and/or al-
terations in metabolism of CSA.
Comparative data of blood pressure, number of blood
pressure medications, and serum creatinine levels suggest
more CSA toxicity in the Neoral than the Sandimmun
group. Biopsies in four of nine of the Neoral recipients
demonstrated no rejection in three (based upon Banft cri-
teria), and suggested CSA toxicity. We are in the process of
lowering our target CSA trough levels to aim for a 10%
reduction in CSA trough level with Neoral compared with
Sandimmun. We believe that by doing this we will see
fewer acute side effects of Neoral and at the same time
provide adequate immunosuppression.
In summary, Neoral has been developed to improve
absorption and to deliver a greater AUC for CSA. Because
children metabolize/eliminate CSA at a higher rate than
adults, they may initially require more frequent dosing of
Neoral. In those patients who do require more frequent
dosing, most can be changed to twice daily dosing within 1
month post transplant.
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Table 1. Creatinine levels, blood pressure (BP), number of BP medications, and biopsy results in Neoral and Sandimmun groupsa, b
Neoral group Sandimmun group Significance
n 9 9 NS
Dose at discharge
(mg/kg per day)
25+2.3 12.4+1.9 P 50.05
Dose at 1 month
(mg/kg per day)
13.7+0.9 13.3+1.2 NS
Creatinine at 1 month 1.1+0.2 mg/dl 1.1+0.2 mg/dl NS
Mean BP at 1 month 122/70 mmHg 131/78 mmHg NS
No. of BP medications at 1 month 2.7+0.2 0.75+0.5 P 50.05
No. of biopsies/first 6 months 4/9 1/9 Not applicable
No. of biopsies with rejection 1/4 1/1 Not applicable
No. of biopsies compatible with CSA toxicityc 3/4 0/0 Not applicable
CSA, Cyclosporine
a Results are mean + SEM
b Statistical analysis performed using Student's t-test
c Normalization of creatinine with decreasing Neoral dose with no subsequent evidence of allograft rejection
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